Daewon Pharmaceutical Co., Ltd. (KRX: 003220)

Market Cap	298.57B
Revenue (ttm)	593.94B
Net Income (ttm)	16.02B
Shares Out	21.43M
EPS (ttm)	756.15
PE Ratio	18.42
Forward PE	8.12
Dividend	300.00 (2.15%)
Ex-Dividend Date	Dec 27, 2024

Volume	50,507
Open	14,080
Previous Close	14,030
Day's Range	13,890 - 14,080
52-Week Range	13,350 - 20,700
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1958
• Employees: 1,260
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003220

Financial Performance

In 2023, Daewon Pharmaceutical's revenue was 526.95 billion, an increase of 10.04% compared to the previous year's 478.88 billion. Earnings were 23.92 billion, a decrease of -25.13%.